JP2016079138A - Amino acid-containing composition - Google Patents
Amino acid-containing composition Download PDFInfo
- Publication number
- JP2016079138A JP2016079138A JP2014213374A JP2014213374A JP2016079138A JP 2016079138 A JP2016079138 A JP 2016079138A JP 2014213374 A JP2014213374 A JP 2014213374A JP 2014213374 A JP2014213374 A JP 2014213374A JP 2016079138 A JP2016079138 A JP 2016079138A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- branched chain
- powder
- composition
- chain amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 31
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 45
- 239000000843 powder Substances 0.000 claims abstract description 43
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 38
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 22
- 235000013336 milk Nutrition 0.000 claims abstract description 20
- 239000008267 milk Substances 0.000 claims abstract description 20
- 210000004080 milk Anatomy 0.000 claims abstract description 20
- 239000002245 particle Substances 0.000 claims abstract description 10
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 56
- 241000237509 Patinopecten sp. Species 0.000 claims description 13
- 235000020637 scallop Nutrition 0.000 claims description 13
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 7
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 7
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 7
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 7
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000176 sodium gluconate Substances 0.000 claims description 2
- 235000012207 sodium gluconate Nutrition 0.000 claims description 2
- 229940005574 sodium gluconate Drugs 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 abstract description 7
- 238000002156 mixing Methods 0.000 abstract description 7
- 238000000576 coating method Methods 0.000 abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 25
- 239000008187 granular material Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 238000005469 granulation Methods 0.000 description 13
- 230000003179 granulation Effects 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 7
- 229960000310 isoleucine Drugs 0.000 description 7
- 239000004474 valine Substances 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- -1 glycerin fatty acid ester Chemical class 0.000 description 6
- 230000003137 locomotive effect Effects 0.000 description 6
- 150000003839 salts Chemical group 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000008407 joint function Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000007711 solidification Methods 0.000 description 3
- 230000008023 solidification Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 229960004998 acesulfame potassium Drugs 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000011361 granulated particle Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明はアミノ酸含有組成物に関する。 The present invention relates to an amino acid-containing composition.
高齢者において、しばしばサルコペニアと呼ばれる特有の骨格筋減少が起こる。そして骨格筋減少が高齢者の活動量を低下させ、この活動量低下が更なる筋力低下をもたらすという悪循環に陥る。活動量の低下は基礎エネルギー代謝をも低下させる。特に寝たきり状態において、この状態が顕著に現れる。 In older people, a characteristic skeletal muscle loss, often called sarcopenia, occurs. And skeletal muscle loss reduces the amount of activity of the elderly, and falls into a vicious circle in which this reduction in activity amount leads to further muscular weakness. Reduced activity also reduces basal energy metabolism. This state is particularly noticeable in the bedridden state.
骨格筋の低下にともなう一連の運動器の障害をロコモティブシンドローム(locomotive syndrome、略して「ロコモ」)と呼ばれている。ロコモの原因である「運動器の障害」の原因には、大きく分けて、「運動器自体の疾患」と、「加齢による運動器機能不全」がある。運動器自体の疾患(筋骨格運動器系)は、加齢に伴う様々な運動器疾患、たとえば変形性関節症、骨粗鬆症に伴う円背、易骨折性、変形性脊椎症、脊柱管狭窄症など、あるいは関節リウマチなどでは、痛み、関節可動域制限、筋力低下、麻痺、骨折、痙性などにより、バランス能力、体力、移動能力の低下をきたす。
また加齢による運動器機能不全は、主として前記の骨格筋減少に由来する。加齢により、身体機能は低下し、筋力低下、持久力低下、反応時間延長、運動速度の低下、巧緻性低下、深部感覚低下、バランス能力低下などが出現する。
ロコモは、「ねたきり」や「要介護」の主要な原因であると指摘されており、「メタボ」や「認知症」と並び、「健康寿命の短縮」、「ねたきりや要介護状態」の3大要因のひとつであるとも言われている。
A series of musculoskeletal disorders associated with skeletal muscle loss is called locomotive syndrome ("locomo" for short). The causes of “motor disorder”, which is the cause of locomotive, can be broadly classified into “disease of the motor itself” and “motor dysfunction due to aging”. Diseases of the musculoskeletal itself (musculoskeletal musculoskeletal system) include various musculoskeletal diseases associated with aging, such as osteoarthritis, dorsum of the osteoporosis, easy fracture, osteoarthritis, and spinal stenosis In rheumatoid arthritis, etc., balance ability, physical strength, movement ability are reduced due to pain, limited range of motion, muscle weakness, paralysis, fracture, spasticity, etc.
In addition, musculoskeletal dysfunction due to aging mainly originates from the aforementioned skeletal muscle loss. With aging, physical function decreases, and muscle strength, endurance, extended reaction time, reduced exercise speed, skill, deep sense, and balance ability appear.
Locomo has been pointed out to be the main cause of “nettaki” and “need nursing care”, and along with “metabo” and “dementia” It is said to be one of the three major factors of "state".
加齢による筋肉の減少は40歳頃から始まるが、筋肉の減少を抑えるためには適度な運動で筋肉に負荷を与え続けること、そしてタンパク質、アミノ酸など、筋肉の材料となる栄養素を摂取することが必要であるといわれている。アミノ酸は、筋肉合成のために必須であり、特に積極的な摂取が進められている。アミノ酸の中でも、ロイシン、イソロイシン、バリンなどの分岐鎖アミノ酸は重要であり、その中でも特にロイシンが重要であると言われている。
さらに、骨格筋の低下の次に加齢による骨の劣化を予防し、関節機能を強化することが重要であるといわれている。骨を強化するためには、「ビタミンD」、関節機能を強化するにはヒアルロン酸やコンドロイチン硫酸などのムコ多糖類、あるいはその前駆体であるN−アセチルグルコサミンの摂取が有効であると言われている。カルシウムは骨を形成するうえで絶対に欠かせない栄養素で、 リンやマグネシウムと共に、骨や歯を形成し、強度を維持するが、 カルシウムの慢性的な不足が続くと、いわゆる骨粗鬆症の状態となり腰痛、骨折のリスクが高まる。 カルシウム不足はロコモに直結する。
Muscle loss due to aging begins around the age of 40, but in order to suppress muscle loss, keep stressing muscles with moderate exercise, and intake nutrients that are muscle materials such as proteins and amino acids. Is said to be necessary. Amino acids are essential for muscle synthesis and are being actively consumed. Among amino acids, branched chain amino acids such as leucine, isoleucine, and valine are important. Among them, leucine is said to be particularly important.
Furthermore, it is said that it is important to prevent the deterioration of the bone due to aging and to strengthen the joint function after the decrease of the skeletal muscle. In order to strengthen bones, it is said that ingestion of “vitamin D”, ingestion of mucopolysaccharides such as hyaluronic acid and chondroitin sulfate, or its precursor N-acetylglucosamine is effective for strengthening joint function. ing. Calcium is an essential nutrient for bone formation. Together with phosphorus and magnesium, it forms bones and teeth and maintains strength, but if chronic calcium deficiency continues, so-called osteoporosis results in low back pain. , The risk of fracture increases. Calcium deficiency is directly linked to Locomo.
ロコモの原因となる筋肉の低下を抑制するための技術が特許出願されている。特許文献1には、分岐鎖アミノ酸であるロイシン、イソロイシン、バリン、リジンを含む高齢者の筋肉低下を抑制する組成物が開示されている。
特許文献2にはロイシン、イソロイシン、バリンと有機酸を含む顆粒剤が開示されている。
これらの先行技術はいずれも大量のアミノ酸を一度に摂取するための製剤についての技術である。またこれらの分岐鎖アミノ酸は水に難溶性であって、飲料に配合することが困難であることが知られている。
また、骨や関節の機能を強化するため、前記したようにN−アセチルグルコサミンとカルシウムを併用して摂取することが普及している。しかし骨強化のためのカルシウムやN−アセチルグルコサミンはいずれも錠剤や顆粒剤である。
本発明者も、飲料に分岐鎖アミノ酸を配合しようと試みているが、溶解度が低くまた風味の問題があって好ましい飲料を調製することが困難であった。
また分岐鎖アミノ酸を牛乳に配合すると、乳蛋白質を構成するアミノ酸に加えて、ロコモ対策に有用な分岐鎖アミノ酸を容易に増強することができるが、難溶性のため、添加した分岐鎖アミノ酸がいわゆるママコ状態となって溶解せず、沈殿が発生するため、所望する量を配合しても、分岐鎖アミノ酸を効率的に摂取できないという問題があった。
A patent application has been filed for a technique for suppressing muscle loss that causes locomotives. Patent Document 1 discloses a composition that suppresses muscle lowering in elderly people, including branched chain amino acids leucine, isoleucine, valine, and lysine.
Patent Document 2 discloses a granule containing leucine, isoleucine, valine and an organic acid.
Each of these prior arts is a technique for a preparation for taking a large amount of amino acid at a time. Further, these branched chain amino acids are known to be hardly soluble in water and difficult to be blended in beverages.
Moreover, in order to reinforce the function of bones and joints, as described above, taking N-acetylglucosamine and calcium in combination has become widespread. However, calcium and N-acetylglucosamine for strengthening bone are both tablets and granules.
The present inventor has also tried to add a branched chain amino acid to a beverage, but it has been difficult to prepare a preferred beverage due to low solubility and flavor problems.
Moreover, when a branched chain amino acid is added to milk, in addition to the amino acid constituting the milk protein, a branched chain amino acid useful for measures against locomo can be easily enhanced. There is a problem that the branched chain amino acid cannot be efficiently ingested even if a desired amount is blended because it does not dissolve in a mamaco state and precipitates.
本発明者は、ロコモ対策として分岐鎖アミノ酸とカルシウムを食品に配合するための技術を研究している。分岐鎖アミノ酸は疎水性であり、水に溶解しにくく、水濡れしにくいため、水や牛乳に溶解したとき、いわゆる「ママコ」状態となってしまい、溶解又は分散しにくい。このため溶解性のある糖類とともに造粒することが通常行われているが、糖類や炭酸カルシウムと共存すると、アミノカルボニル反応により褐変や固結するという新たな課題が出現する。また関節機能を健全に保つN−アセチルグルコサミンを配合すると共存するグルコサミンによって褐変するという課題がある。またカルシウムとして広く利用されている炭酸カルシウムは、牛乳中では沈殿しやすいという問題がある。
本発明が解決しようとする課題は、ロコモ対策のために牛乳に溶解させて飲用する組成物であって、牛乳に溶解分散しやすく、保存中に褐変しにくく、固結しづらい分岐鎖アミノ酸と炭酸カルシウムを含有する顆粒状組成物を提供することである。
The present inventor is researching a technique for blending a branched chain amino acid and calcium into a food as a measure against locomo. Branched chain amino acids are hydrophobic, are not easily dissolved in water, and are not easily wetted with water. Therefore, when they are dissolved in water or milk, they are in a so-called “mamako” state and are not easily dissolved or dispersed. For this reason, granulation with a soluble saccharide is usually performed. However, when it coexists with a saccharide or calcium carbonate, a new problem of browning or solidification due to an aminocarbonyl reaction appears. Moreover, when N-acetylglucosamine which keeps joint function healthy is mix | blended, there exists a subject of browning with the coexisting glucosamine. In addition, calcium carbonate, which is widely used as calcium, has a problem of being easily precipitated in milk.
The problem to be solved by the present invention is a composition that is dissolved in milk for drinking against locomotive, and is easily dissolved and dispersed in milk, is not easily browned during storage, and is difficult to solidify. It is to provide a granular composition containing calcium carbonate.
上記課題を解決するべく種々検討した結果、分岐鎖アミノ酸を含むアミノ酸混合粉末と糖類とクエン酸粉末を造粒し、さらに粒子の表面に乳化剤を噴霧して得られる顆粒に炭酸カルシウム粉末を混合することで、褐変が抑制され、しかも牛乳に溶解させると炭酸カルシウムとクエン酸が相互作用して発泡し、粉末粒子を分散させて、容易に溶解・分散する組成物となることを見出し、本発明を完成させた。 As a result of various studies to solve the above problems, a mixture of amino acids containing branched chain amino acids, saccharides and citric acid powder is granulated, and further, calcium carbonate powder is mixed with granules obtained by spraying an emulsifier on the surface of the particles. Thus, it is found that browning is suppressed, and when dissolved in milk, calcium carbonate and citric acid interact to foam, disperse the powder particles, and easily dissolve and disperse the composition. Was completed.
すなわち、本発明は次の構成である。
(1)分岐鎖アミノ酸を含むアミノ酸粉末とクエン酸を含む粒子の表面を乳化剤で被覆した粒子と、炭酸カルシウム粉末を含む粉末組成物。
(2)炭酸カルシウム粉末がホタテ貝殻粉末である(1)に記載の組成物。
(3)クエン酸を3〜7質量%含有する(1)又は(2)に記載の組成物。
(4)分岐鎖アミノ酸を全アミノ酸中50質量%以上含有する(1)〜(3)のいずれかに記載の組成物。
(5)さらにグルコン酸ナトリウムとN−アセチルグルコサミンを含む(4)に記載の組成物。
(6)分岐鎖アミノ酸が10質量%以上含有されている(1)〜(5)のいずれかに記載の組成物。
(7)炭酸カルシウムが5質量%以上含有されている(6)に記載の組成物。
(8)牛乳に溶解・分散させて飲用するための(1)〜(7)のいずれかに記載の組成物。
That is, the present invention has the following configuration.
(1) A powder composition comprising an amino acid powder containing a branched chain amino acid, particles obtained by coating the surface of particles containing citric acid with an emulsifier, and calcium carbonate powder.
(2) The composition according to (1), wherein the calcium carbonate powder is scallop shell powder.
(3) The composition as described in (1) or (2) which contains 3-7 mass% of citric acid.
(4) The composition according to any one of (1) to (3), which contains 50% by mass or more of branched chain amino acids in all amino acids.
(5) The composition according to (4), further comprising sodium gluconate and N-acetylglucosamine.
(6) The composition according to any one of (1) to (5), wherein 10% by mass or more of branched chain amino acid is contained.
(7) The composition according to (6), wherein 5% by mass or more of calcium carbonate is contained.
(8) The composition according to any one of (1) to (7), which is used after being dissolved and dispersed in milk.
本発明に係る組成物は、牛乳に速やかに溶解分散し、沈殿が生じない。また本発明の粉末を溶解させた牛乳に、分岐鎖アミノ酸に由来する異味、異臭が無く、きわめて飲用しやすい飲料となる。さらに、粉末を保存した場合の褐変や固結が生じず、安定である。
また、本発明の組成物は、分岐鎖アミノ酸による筋肉の増強や抑制防止、カルシウムによる骨強化、N−アセチルグルコサミンによる関節機能の強化が期待できる。
The composition according to the present invention dissolves and disperses quickly in milk, and no precipitation occurs. Moreover, the milk in which the powder of the present invention is dissolved has no off-flavors and off-flavors derived from branched chain amino acids, and is a beverage that is extremely easy to drink. Furthermore, it is stable without browning or solidification when the powder is stored.
In addition, the composition of the present invention can be expected to strengthen and prevent inhibition of muscle with branched chain amino acids, strengthen bone with calcium, and strengthen joint function with N-acetylglucosamine.
本発明は、牛乳に溶解又は分散させて飲用するための組成物であって、分岐鎖アミノ酸を含むアミノ酸粉末とクエン酸を含む粒子の表面を乳化剤で被覆した粒子と、炭酸カルシウム粉末を含む粉末組成物に係るものである。
本発明に係る組成物は、バリン、ロイシンおよびイソロイシンよりなる群から選ばれる1種以上の分岐鎖アミノ酸を組成物あたり総量で10〜40質量%含有することが好ましい。
The present invention relates to a composition for drinking after being dissolved or dispersed in milk, and comprising an amino acid powder containing a branched chain amino acid and particles containing citric acid coated with an emulsifier, and a powder containing calcium carbonate powder It relates to the composition.
The composition according to the present invention preferably contains 10 to 40% by mass of a total amount of one or more branched chain amino acids selected from the group consisting of valine, leucine and isoleucine per composition.
本発明に係る組成物において用いる分岐鎖アミノ酸は、バリン、ロイシン及びイソロイシンよりなる群から選ばれる1種以上を含む。これら分岐鎖アミノ酸の形態は特に制限されず、例えば、タンパク質の形態、ペプチドの形態、塩の形態、遊離の形態等のいずれの形態でも用いることができる。遊離アミノ酸の形態が最も好ましい。この場合、L体、D体、DL体のいずれをも用いることができる。しかし、L体が最も好適に用いられる。また、前記分岐鎖アミノ酸としては、これらを含有する動植物等から抽出し精製したものや、化学合成法、発酵法、遺伝子組み換え法によって得られるもののいずれを使用してもよい。 The branched chain amino acid used in the composition according to the present invention includes one or more selected from the group consisting of valine, leucine and isoleucine. The form of these branched chain amino acids is not particularly limited, and for example, any form such as a protein form, a peptide form, a salt form, and a free form can be used. The free amino acid form is most preferred. In this case, any of L-form, D-form, and DL-form can be used. However, L-form is most preferably used. In addition, as the branched chain amino acid, any of those extracted and purified from animals and plants containing them, or those obtained by chemical synthesis, fermentation, or genetic recombination may be used.
本発明組成物において用いる分岐鎖アミノ酸は、全てが単一の形態であってもよいし、あるいは異なる2種以上の形態であってもよい。例えば、分岐鎖アミノ酸は、遊離の形態の分岐鎖アミノ酸のみからなるものであってもよいし、遊離の形態の分岐鎖アミノ酸とタンパク質の形態の分岐鎖アミノ酸とを含むもの等であってもよい。本発明に係る組成物が遊離の形態の分岐鎖アミノ酸を含有する場合、その含有量は、組成物あたり総量で10質量%以上が好ましく、10〜15質量%とすることが特に好ましい。
なお、本明細書において、分岐鎖アミノ酸の量は遊離形態換算量である。
The branched chain amino acids used in the composition of the present invention may all be in a single form or may be in two or more different forms. For example, the branched chain amino acid may be composed only of a free form of a branched chain amino acid, or may include a free form of a branched chain amino acid and a protein form of a branched chain amino acid. . When the composition according to the present invention contains a free-form branched-chain amino acid, the content is preferably 10% by mass or more, particularly preferably 10 to 15% by mass, based on the total amount of the composition.
In the present specification, the amount of the branched chain amino acid is a free form equivalent amount.
本発明の組成物において用いる分岐鎖アミノ酸は、バリン、ロイシン及びイソロイシンを含むことが好ましく、その場合、ロイシン、イソロイシン及びバリンの配合割合は、通常、重量比で、ロイシン:イソロイシン:バリン=4:1:1〜3:1:1である。 The branched chain amino acid used in the composition of the present invention preferably contains valine, leucine and isoleucine. In that case, the blending ratio of leucine, isoleucine and valine is usually in a weight ratio of leucine: isoleucine: valine = 4: 1: 1 to 3: 1: 1.
本発明においては、分岐鎖アミノ酸に加えて、その他のアミノ酸を含むことができる。特に本発明のロコモ対策のためには、スレオニン、フェニアルアラニン、メチオニン、トリプトファン、リジンなどの必須アミノ酸及びヒスチジンなどの非必須アミノ酸を添加することが好ましい。
これらの、その他アミノ酸は、分岐鎖アミノ酸と同様に形態は特に制限されず、例えば、タンパク質の形態、ペプチドの形態、塩の形態、遊離の形態等のいずれの形態でも用いることができる。遊離アミノ酸の形態が最も好ましい。この場合、L体、D体、DL体のいずれをも用いることができる。しかし、L体が最も好適に用いられる。分岐鎖アミノ酸は、この組成物当たり10〜40質量%、全アミノ酸当たり40〜60質量%含有させることが好ましい。
本発明に係る組成物が遊離の形態の上記のその他のアミノ酸を含有する場合、その含有量は、全アミノ酸含有量に対して30質量%、組成物あたり10質量%程度とすることが好ましい。
In the present invention, in addition to branched-chain amino acids, other amino acids can be included. In particular, for the countermeasure against locomo of the present invention, it is preferable to add essential amino acids such as threonine, phenylalanine, methionine, tryptophan, lysine and non-essential amino acids such as histidine.
The form of these other amino acids is not particularly limited in the same manner as the branched chain amino acid, and can be used in any form such as a protein form, a peptide form, a salt form, and a free form. The free amino acid form is most preferred. In this case, any of L-form, D-form, and DL-form can be used. However, L-form is most preferably used. The branched chain amino acid is preferably contained in an amount of 10 to 40% by mass and 40 to 60% by mass per total amino acid.
When the composition according to the present invention contains the above-mentioned other amino acids in a free form, the content is preferably about 30% by mass with respect to the total amino acid content and about 10% by mass per composition.
本発明に係る組成物において用いるクエン酸は、かんきつ類から抽出された天然クエン酸、あるいは微生物醗酵法で製造されたもの、あるいは化学合成されたものであっても使用可能である。クエン酸の含有量は、本発明の組成物当たり1〜10質量%、好ましくは3〜7質量%である。クエン酸は牛乳に溶解すると炭酸カルシウムと反応し、微小の二酸化炭素の気泡を形成し、アミノ酸の分散を促進し、さらに炭酸カルシウムなどの沈降性の粒子を内包して沈降を抑制する。
クエン酸は、分岐鎖アミノ酸及びその他のアミノ酸と混合し、造粒する。
Citric acid used in the composition according to the present invention may be natural citric acid extracted from citrus fruits, produced by microbial fermentation, or chemically synthesized. The content of citric acid is 1 to 10% by mass, preferably 3 to 7% by mass, based on the composition of the present invention. When citric acid dissolves in milk, it reacts with calcium carbonate to form minute carbon dioxide bubbles, promotes amino acid dispersion, and further contains sedimentation particles such as calcium carbonate to suppress sedimentation.
Citric acid is mixed with branched chain amino acids and other amino acids and granulated.
造粒された粒子には、上記したアミノ酸粉末及びクエン酸以外に、賦形剤、結合剤、崩壊剤など許容される添加剤を含有することができる。賦形剤としては、当該分野で公知のものを幅広く使用することが可能であり、例えば、乳糖、白糖、ブドウ糖、D−マンニトール、マルチトール、キシリトール、エリスリトール、D−ソルビトール、マルトース、デンプンおよびデンプン誘導体、アスパルテーム、グリチルリチン酸およびその塩、サッカリンおよびその塩、ステビアおよびその塩、スクラロース、アセスルファムカリウム、リン酸水素カルシウム等が挙げられる。本発明においては還元麦芽糖あるいはエリスリトールが好ましい。 In addition to the above-mentioned amino acid powder and citric acid, the granulated particles can contain acceptable additives such as excipients, binders and disintegrants. As the excipient, those known in the art can be widely used. For example, lactose, sucrose, glucose, D-mannitol, maltitol, xylitol, erythritol, D-sorbitol, maltose, starch and starch Derivatives, aspartame, glycyrrhizic acid and its salts, saccharin and its salts, stevia and its salts, sucralose, acesulfame potassium, calcium hydrogen phosphate and the like. In the present invention, reduced maltose or erythritol is preferred.
結合剤としては、当該分野で公知のものを広く使用することが可能であり、例えばヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン、メチルセルロース、デキストリン、デンプンおよびデンプン誘導体、デンプン分解物、グァーガム、アラビアゴム、トラガント、アルギン酸およびその塩、プルラン、カラギーナン、ゼラチン、寒天、等が挙げられる。本発明においてはデンプン分解物が好ましい。 As the binder, those known in the art can be widely used. For example, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, methylcellulose, dextrin, starch and starch derivatives, starch degradation products, guar gum, gum arabic , Tragacanth, alginic acid and salts thereof, pullulan, carrageenan, gelatin, agar, and the like. In the present invention, starch degradation products are preferred.
顆粒を造粒する製造方法は、特に限定されず、当該分野で公知の方法を幅広く使用することが可能であり、具体的には、押し出し造粒法、転動造粒法、撹拌造粒法、流動造粒法、転動流動造粒法、混練造粒法等が挙げられる。これらの中でも、流動造粒法や撹拌造粒法が好ましい。
造粒されたアミノ酸・クエン酸顆粒の嵩密度(嵩比重)は、特に限定されないが、0.30〜0.60g/mLが好ましく、0.35〜0.55g/mLがさらに好ましく、0.35〜0.40g/mLが特に好ましい。
造粒にあたっては、流動造流装置を用いて、バインダー兼被覆剤としてグリセリン脂肪酸エステルを噴霧して、造粒と被覆を同時に行う。グリセリンエステルとしては、酢酸モノグリセリド、乳酸モノグリセリド、クエン酸モノグリセリド、ジアセチル酒石酸モノグリセリド、コハク酸モノグリセリド、ポリグリセリン脂肪酸エステル、ポリグリセリン縮合リシノール酸エステルなどが例示できる。本発明にあっては、食品添加物として許可されているグリセリン脂肪酸エステルであればどのようなものでも使用可能である。特に好ましくは麺ほぐれ剤として市販されているグリセリンエステルであり、具体的な商品としては理研ビタミン株式会社製エマテックW−700を例示することができる。
被覆量はアミノ酸を含む顆粒当たり、0.1質量%以上とする。本発明組成物の牛乳への分散性とコーティング効果を考慮すると、約0.5〜1質量%とすることが特に好ましい。
The production method for granulating the granule is not particularly limited, and a wide variety of methods known in the art can be used. Specifically, extrusion granulation, rolling granulation, stirring granulation , Fluidized granulation method, rolling fluidized granulation method, kneading granulation method and the like. Among these, fluid granulation method and stirring granulation method are preferable.
The bulk density (bulk specific gravity) of the granulated amino acid / citric acid granules is not particularly limited, but is preferably 0.30 to 0.60 g / mL, more preferably 0.35 to 0.55 g / mL, and 35 to 0.40 g / mL is particularly preferable.
In the granulation, the glycerin fatty acid ester is sprayed as a binder and coating agent by using a fluid flow apparatus, and granulation and coating are performed simultaneously. Examples of the glycerin ester include acetic acid monoglyceride, lactic acid monoglyceride, citric acid monoglyceride, diacetyltartaric acid monoglyceride, succinic acid monoglyceride, polyglycerin fatty acid ester, polyglycerin condensed ricinoleic acid ester and the like. In the present invention, any glycerin fatty acid ester permitted as a food additive can be used. Particularly preferred is a glycerin ester marketed as a noodle loosening agent. Specific examples of such products include Ematec W-700 manufactured by Riken Vitamin Co., Ltd.
The coating amount is 0.1% by mass or more per granule containing amino acids. Considering the dispersibility of the composition of the present invention in milk and the coating effect, it is particularly preferably about 0.5 to 1% by mass.
なお、得られた顆粒の水分の乾燥処理を行うことが好ましい。乾燥処理は、原顆粒剤の水分が2%以下になるまで乾燥することが好ましい。乾燥の方法は特に限定されず、通常の顆粒乾燥に用いる乾燥方法であればどのような方法であっても採用できるが、真空乾燥法及び送風乾燥法は好ましい。真空乾燥法と送風乾燥法は、それぞれ単独で実施しても、併用によってもよい。しかしながら、真空乾燥法を用いると、可能な限り顆粒剤の水分を除去することができるため、特に好ましい。 In addition, it is preferable to perform the drying process of the water | moisture content of the obtained granule. The drying treatment is preferably performed until the moisture content of the original granule becomes 2% or less. The drying method is not particularly limited, and any method can be adopted as long as it is a drying method used for ordinary granule drying, but the vacuum drying method and the air drying method are preferable. The vacuum drying method and the blast drying method may be carried out independently or in combination. However, it is particularly preferable to use a vacuum drying method because the moisture of the granules can be removed as much as possible.
このようにして得られた顆粒をさらに炭酸カルシウムの粉末と粉混合して、本発明の組成物とする。
発明に係る組成物において用いる炭酸カルシウムは、食品または医薬品規格のものであればどのような由来のものであっても使用可能である。例えば、石灰岩の粉末、あるいは卵殻粉末、カキ殻粉末、ホタテ貝殻石灰(ホタテ貝殻粉末)などが例示できる。特に好ましくはホタテ貝殻粉末である。ホタテ貝殻粉末は、ホタテ貝の殻を粉砕したもので、微小な多孔性の構造を有しており、酸性の水溶液と反応して二酸化炭素を発生させるが、この二酸化炭素の気泡により、溶液中での沈降が抑制されるため、本発明においては特に好ましい。このような市販の炭酸カルシウムとしては、株式会社エヌ・シー・コーポレーション製のホタテ末、ホタテ末Sを例示できる
炭酸カルシウム粉末は、本発明の組成物当たり1〜10質量%、好ましくは3〜7質量%、特に好ましくは5質量%以上である。
本発明に係る組成物には、上記の造粒したアミノ酸・クエン酸顆粒と炭酸カルシウム粉末を混合する際にロコモの改善に必要とされるビタミン、あるいは甘味料、その他風味を改善する成分を配合することができる。ビタミンとしては、ビタミンK含有粉末、ビタミンD含有粉末を例示できる。甘味料としてはスクラロース、アセスルファムカリウム、還元パラチノース、ネオテームを例示することができる。
The granules thus obtained are further mixed with calcium carbonate powder to obtain the composition of the present invention.
The calcium carbonate used in the composition according to the invention can be of any origin as long as it is of food or pharmaceutical standards. Examples thereof include limestone powder, eggshell powder, oyster shell powder, and scallop shell lime (scallop shell powder). Particularly preferred is scallop shell powder. Scallop shell powder is a crushed shell of scallop shell and has a fine porous structure. It reacts with an acidic aqueous solution to generate carbon dioxide. In the present invention, it is particularly preferable since sedimentation at the bottom is suppressed. Examples of such commercially available calcium carbonate include scallop powder and scallop powder S manufactured by NC Corporation. The calcium carbonate powder is 1 to 10% by mass, preferably 3 to 7% per composition of the present invention. % By mass, particularly preferably 5% by mass or more.
The composition according to the present invention contains vitamins, sweeteners, and other flavor-improving ingredients required to improve locomo when mixing the granulated amino acid / citrate granules and calcium carbonate powder. can do. Examples of vitamins include vitamin K-containing powder and vitamin D-containing powder. Examples of sweeteners include sucralose, acesulfame potassium, reduced palatinose, and neotame.
かくして得られる組成物は、牛乳に速やかに溶解・分散し、牛乳に好ましい風味を与え、さらにはロコモティブシンドロームの患者の症状を改善することが期待される。 The composition thus obtained is expected to dissolve and disperse quickly in milk, impart a favorable flavor to milk, and further improve the symptoms of patients with locomotive syndrome.
次に実施例、比較例に基づいて本発明を説明する。 Next, this invention is demonstrated based on an Example and a comparative example.
1.粉末組成物の調製
高齢者に対する最適のロコモティブシンドローム対策の栄養効果を考慮し、表1の組成で分岐鎖アミノ酸を含む栄養組成物を調製した。なお、アミノ酸混合物は、アミノ酸粉末をあらかじめ表2の規格であらかじめ粉混合したものを用いた。
1. Preparation of Powder Composition In consideration of the nutritional effect of optimal countermeasures against locomotive syndrome for the elderly, a nutritional composition containing branched chain amino acids with the composition shown in Table 1 was prepared. The amino acid mixture was prepared by previously mixing amino acid powder in accordance with the specifications shown in Table 2.
表1組成の造粒部を造粒するにあたっては株式会社パウレック製流動造流装置MP−01を用いて、1回のバッチ量を300gとして、吸気温度60℃、排気温度40℃、スプレーエア圧0.4MPa、スプレーエア流量25L/時間、噴霧速度16g/分の条件で行った。なお造粒に際し、バインダー兼被膜剤として、前述のエマテックW−700を用いた。
得られたアミノ酸・クエン酸顆粒の嵩密度は0.35〜0.38g/mLであった。また粒径はJIS篩で18メッシュPASSであった。
When granulating the granulation part of Table 1, using a flow flow apparatus MP-01 manufactured by POWREC Co., Ltd., the batch amount is 300 g, the intake temperature is 60 ° C., the exhaust temperature is 40 ° C., the spray air pressure The test was performed under the conditions of 0.4 MPa, a spray air flow rate of 25 L / hour, and a spray rate of 16 g / minute. In the granulation, Ematech W-700 described above was used as a binder and coating agent.
The bulk density of the obtained amino acid / citric acid granules was 0.35 to 0.38 g / mL. The particle size was 18 mesh PASS with a JIS sieve.
この顆粒を下記の表3の組成になるように後添加に粉末を加え、粉混合して本発明品とした。なお、下記の食用ホタテ貝殻末は株式会社エヌ・シー・コーポレーションの「ホタテ末、500メッシュパス95%以上」のものを用いた。 The granules were added to the post-addition so as to have the composition shown in Table 3 below, and mixed to obtain a product of the present invention. In addition, the following edible scallop shell powder used was “Scallop powder, 500 mesh pass 95% or more” manufactured by NC Corporation.
2.比較例
本発明品と比較するため、下記表4の組成の顆粒を同様にして調製し、これを後添加成分と混合し、同様の粉末祖組成物である比較例1,2,3を得た。
2. Comparative Example In order to compare with the product of the present invention, a granule having the composition shown in Table 4 below was prepared in the same manner, and this was mixed with the post-added component to obtain Comparative Examples 1, 2, and 3 having the same powder composition. It was.
3.溶解性試験、風味試験
実施例1、比較例1〜3の製品を各9.6g秤量し、これを室温で牛乳180mlに添加し、1分間スパーテルで撹拌し、粉末の溶解性を目視で確認するとともに、各製品を溶解した牛乳の風味を専門パネルにより評価した。溶解性の評価基準は、アミノ酸に由来すると予想される「ママコ」の発生の有無で評価した。
評価結果を下記表5に示す。
3. Solubility test, flavor test 9.6 g each of the products of Example 1 and Comparative Examples 1 to 3 were weighed, added to 180 ml of milk at room temperature, stirred with a spatula for 1 minute, and the powder solubility was visually confirmed. In addition, the flavor of milk in which each product was dissolved was evaluated by a specialized panel. The evaluation standard of solubility was evaluated by the presence or absence of occurrence of “mamako” which is expected to be derived from amino acids.
The evaluation results are shown in Table 5 below.
風味はいずれも良好であった。しかし炭酸カルシウムをあらかじめ造粒した比較例1、2は溶解・分散性において明らかに劣っていた。 The flavor was good. However, Comparative Examples 1 and 2 in which calcium carbonate was previously granulated were clearly inferior in solubility and dispersibility.
4.保存安定性試験
実施例、及び比較例1〜3の組成物を、それぞれ5gを秤量し、密封可能なアルミ袋に入れ、40℃、湿度75%で7日間保管した後、開封し、組成物の褐変および粉末の固結の状態を確認した。
結果を表6に示す。
4). Storage Stability Test Each of the compositions of Examples and Comparative Examples 1 to 3 was weighed and placed in a sealable aluminum bag, stored at 40 ° C. and 75% humidity for 7 days, then opened, and then the composition The state of browning and solidification of the powder was confirmed.
The results are shown in Table 6.
本発明の実施例は褐変も固結も発生しなかった。 In the examples of the present invention, neither browning nor consolidation occurred.
5.クエン酸配合による効果確認試験
実施例の製品を製造するに際し、クエン酸を配合せずに製品を調製し、これを比較例4とした。実施例、比較例4の製品を溶解性試験と同様の条件で牛乳に溶解させ、これを100ml採取し、1500×gで、1分間遠心分離し、不溶解物を強制沈殿させた。遠心管中の沈殿物を回収し、これに0.05Mのクエン酸水溶液を滴下したところ、比較例4の沈殿物は、発泡が観察された。これに対して実施例の沈殿物は、このような発泡現象が観察されなかった。
この試験から、クエン酸を含まない比較例4の組成物を牛乳に溶解させた場合、ホタテ貝殻末(炭酸カルシウム)が沈殿することが明らかとなった。一方、実施例の製品は、発泡現象が観察されなかったことから、ホタテ貝殻末の沈殿が抑制されているものと判断した。
5. Effect confirmation test by citric acid blending In producing the product of the example, the product was prepared without blending citric acid, and this was designated as Comparative Example 4. The product of Example and Comparative Example 4 was dissolved in milk under the same conditions as in the solubility test, and 100 ml of this was collected and centrifuged at 1500 × g for 1 minute to forcibly precipitate insoluble matter. When the precipitate in the centrifuge tube was collected and 0.05 M aqueous citric acid solution was added dropwise thereto, foaming of the precipitate of Comparative Example 4 was observed. On the other hand, no such foaming phenomenon was observed in the precipitates of Examples.
From this test, it was revealed that scallop shell powder (calcium carbonate) was precipitated when the composition of Comparative Example 4 containing no citric acid was dissolved in milk. On the other hand, since the foaming phenomenon was not observed in the products of the examples, it was judged that precipitation of scallop shell powder was suppressed.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014213374A JP6435161B2 (en) | 2014-10-20 | 2014-10-20 | Amino acid-containing composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014213374A JP6435161B2 (en) | 2014-10-20 | 2014-10-20 | Amino acid-containing composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016079138A true JP2016079138A (en) | 2016-05-16 |
JP6435161B2 JP6435161B2 (en) | 2018-12-05 |
Family
ID=55957548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014213374A Active JP6435161B2 (en) | 2014-10-20 | 2014-10-20 | Amino acid-containing composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6435161B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019011299A (en) * | 2017-06-30 | 2019-01-24 | 小林製薬株式会社 | Oral composition with carbohydrate material coated with non-amino acid material |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003221326A (en) * | 2002-01-25 | 2003-08-05 | Ajinomoto Co Inc | Chewable agent containing branched amino acids |
JP2006070024A (en) * | 2004-08-05 | 2006-03-16 | Meiji Milk Prod Co Ltd | Granular formulation and method for producing the same |
WO2007123113A1 (en) * | 2006-04-17 | 2007-11-01 | Meiji Seika Kaisha, Ltd. | Whey protein-containing granules and method of producing the same |
JP2008239586A (en) * | 2007-03-29 | 2008-10-09 | Nof Corp | Zein-covered branched-chain amino acid powder |
JP2014034556A (en) * | 2012-08-09 | 2014-02-24 | Fancl Corp | Orally rapid disintegrating tablet |
-
2014
- 2014-10-20 JP JP2014213374A patent/JP6435161B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003221326A (en) * | 2002-01-25 | 2003-08-05 | Ajinomoto Co Inc | Chewable agent containing branched amino acids |
JP2006070024A (en) * | 2004-08-05 | 2006-03-16 | Meiji Milk Prod Co Ltd | Granular formulation and method for producing the same |
WO2007123113A1 (en) * | 2006-04-17 | 2007-11-01 | Meiji Seika Kaisha, Ltd. | Whey protein-containing granules and method of producing the same |
JP2008239586A (en) * | 2007-03-29 | 2008-10-09 | Nof Corp | Zein-covered branched-chain amino acid powder |
JP2014034556A (en) * | 2012-08-09 | 2014-02-24 | Fancl Corp | Orally rapid disintegrating tablet |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019011299A (en) * | 2017-06-30 | 2019-01-24 | 小林製薬株式会社 | Oral composition with carbohydrate material coated with non-amino acid material |
Also Published As
Publication number | Publication date |
---|---|
JP6435161B2 (en) | 2018-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5909791B1 (en) | Xanthan gum granulated product and thickening composition | |
JP6435161B2 (en) | Amino acid-containing composition | |
WO2014034176A1 (en) | Granules and process for producing granules | |
WO2015137387A1 (en) | Muscle enhancing drug | |
JP5454142B2 (en) | Low-volume production method of solid preparation with high amino acid content | |
JP6267862B2 (en) | Jellied composition | |
JP2007222857A (en) | Powdered granulation method and powdered easily soluble granule composition | |
JP6189567B1 (en) | Method for producing protein-containing granules | |
JP2009013143A (en) | Sleep-improving composition | |
JP2010254580A (en) | Method for producing arginine-containing tablet | |
JP5574677B2 (en) | Glutamine-containing nutritional composition | |
JP2009095341A (en) | Lump-preventing agent for thickening polysaccharides | |
JP2022098308A (en) | Granular oral composition primarily composed of aspartic acid or salt thereof | |
CN105288638B (en) | A kind of method for improving branched-chain amino acid pulvis bulk density | |
JP3199097U (en) | Tablets containing black vinegar glucosamine mixture | |
JP5467751B2 (en) | Amino acid-containing solid composition with suppressed protein coagulation action | |
JP2007022982A (en) | Ameliorating agent for bowel movement and food for ameliorating bowel movement | |
JP2003063951A (en) | Tablet and method for producing the same | |
JP5270893B2 (en) | Process for producing rapidly disintegrating granules containing off-flavor ingredients | |
JP2005343862A (en) | Mineral-containing preparation and its use | |
CN110944526B (en) | Nutritional tablet and preparation method thereof | |
JPWO2017002718A1 (en) | Splice formation inhibitor | |
JP2011254709A (en) | Food quality improving agent | |
JP6670287B2 (en) | Jelly composition | |
JP2010095474A (en) | Calcium absorption-promoting composition and calcium absorption-promoting food and drink |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170620 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180514 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180514 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181112 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6435161 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |